21![BEIKE BIOTECHNOLOGY Patient Case Study Spinal Muscular Atrophy Type 3 Female, 30 years old, March - April 2010 Background Age: 30 years old BEIKE BIOTECHNOLOGY Patient Case Study Spinal Muscular Atrophy Type 3 Female, 30 years old, March - April 2010 Background Age: 30 years old](https://www.pdfsearch.io/img/e7cb6e3931c29027d7ad99096388d023.jpg) | Add to Reading ListSource URL: beikebiotech.comLanguage: English - Date: 2014-06-23 22:47:05
|
---|
22![BEIKE BIOTECHNOLOGY Patient Case Study Spinal Muscular Atrophy Type 1 Male, 3 years old, May - June 2010 Background Age: 3 years old BEIKE BIOTECHNOLOGY Patient Case Study Spinal Muscular Atrophy Type 1 Male, 3 years old, May - June 2010 Background Age: 3 years old](https://www.pdfsearch.io/img/2ebdaa7b71c7072882651417afc08505.jpg) | Add to Reading ListSource URL: beikebiotech.comLanguage: English - Date: 2014-06-23 22:47:04
|
---|
23![Dear Spinal Muscular Atrophy Community Members, We would like to update you on the clinical development of RG7800, an investigational SMN2 splicing modifier that is being studied as a potential treatment for spinal muscu Dear Spinal Muscular Atrophy Community Members, We would like to update you on the clinical development of RG7800, an investigational SMN2 splicing modifier that is being studied as a potential treatment for spinal muscu](https://www.pdfsearch.io/img/10da68200b549ca982314cfb1e68ac34.jpg) | Add to Reading ListSource URL: www.sma-schweiz.chLanguage: English - Date: 2015-05-07 03:16:04
|
---|
24![SMA Europe 7th Call for Research Projects SMA Europe 7th Call for Research Projects](https://www.pdfsearch.io/img/1b27d2a2e401a00ae1d39a11b8da5356.jpg) | Add to Reading ListSource URL: www.sma-europe.euLanguage: English - Date: 2014-08-01 15:30:46
|
---|
25![NUTRITION BASICS Fostering Health and Growth for Spinal Muscular Atrophy SMA Care Series
Contents NUTRITION BASICS Fostering Health and Growth for Spinal Muscular Atrophy SMA Care Series
Contents](https://www.pdfsearch.io/img/afd2bae716930500f232c9eae5e1009e.jpg) | Add to Reading ListSource URL: www.fsma.org.hkLanguage: English - Date: 2013-04-29 02:31:34
|
---|
26![Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole](https://www.pdfsearch.io/img/29ae16720ab16ee92a18925a7e29c397.jpg) | Add to Reading ListSource URL: www.promotingexcellence.orgLanguage: English - Date: 2009-11-09 18:45:05
|
---|
27![npg Call in the backup The most common genetic killer of infants, a disease known as spinal muscular atrophy, is caused by mutations in a single gene. The human genome contains its own backup system—near-identical cop npg Call in the backup The most common genetic killer of infants, a disease known as spinal muscular atrophy, is caused by mutations in a single gene. The human genome contains its own backup system—near-identical cop](https://www.pdfsearch.io/img/d4266e5f944e4f45eaa96dc6585a3ec8.jpg) | Add to Reading ListSource URL: www.fsma.org.hkLanguage: English - Date: 2013-04-29 02:31:53
|
---|
28![ISIS INITIATES PHASE 1 CLINICAL STUDY OF ISIS-SMNRX IN PATIENTS WITH SPINAL MUSCULAR ATROPHY U.S. FDA has granted both Fast Track Status and Orphan Drug Designation for ISIS-SMNRx CARLSBAD, Calif., December 19, 2011 – ISIS INITIATES PHASE 1 CLINICAL STUDY OF ISIS-SMNRX IN PATIENTS WITH SPINAL MUSCULAR ATROPHY U.S. FDA has granted both Fast Track Status and Orphan Drug Designation for ISIS-SMNRx CARLSBAD, Calif., December 19, 2011 –](https://www.pdfsearch.io/img/534b0b4a74c72646f0e001e1a28bc4fa.jpg) | Add to Reading ListSource URL: www.fsma.org.hkLanguage: English - Date: 2013-04-29 02:31:35
|
---|
29![Happy couple enjoying the surrounding Happy couple enjoying the surrounding](https://www.pdfsearch.io/img/3cb49c7b052fda8ceb7316b53ee1d084.jpg) | Add to Reading ListSource URL: www.vcgs.org.auLanguage: English - Date: 2013-04-28 20:01:23
|
---|
30![AMYOTROPHIC LATERAL SCLEROSIS (ALS) (also known as Lou Gehrig’s Disease) DISEASE FACT SHEET AND OPPORTUNITY FOR TIRASEMTIV What is ALS? About Us Cytokinetics is a clinical-stage biopharmaceutical company AMYOTROPHIC LATERAL SCLEROSIS (ALS) (also known as Lou Gehrig’s Disease) DISEASE FACT SHEET AND OPPORTUNITY FOR TIRASEMTIV What is ALS? About Us Cytokinetics is a clinical-stage biopharmaceutical company](https://www.pdfsearch.io/img/99f57401c5e0854fc179e773d913eda8.jpg) | Add to Reading ListSource URL: www.cytokinetics.comLanguage: English - Date: 2015-02-24 12:44:30
|
---|